Medpace Holdings, Inc.
No enriched coverage for $MEDP in the last 7 days.
Troendle August J. (President & CEO) sold 24,741 shares of Medpace Holdings, Inc. (MEDP) at an average of $621.00 ($620.84–$621.29, $15.36M total) across 2 trades over 2026-09-15 to 2026-09-16.
Troendle August J. (President & CEO) sold 650 shares of Medpace Holdings, Inc. (MEDP) at $620.27 ($0.40M total) on 2026-08-27.
Medpace Holdings insider sold shares worth $2,383,511, according to an SEC filing. The company's stock has seen a 5-day change of -1.79% and a year-to-date change of -3.24%.
Recent MEDP coverage spans insider activity and financial news.
In the last 30 days, MEDP insiders filed 13 SEC Form 4 transactions — no purchases and 13 sales ($66.9M). The most active reporter was Troendle August J., President & CEO, with 9 filings.
Large insider sell may signal confidence concerns, potentially pressuring the stock.
Insider sale by the CEO may signal reduced confidence, but the amount is modest relative to holdings.
Medpace Holdings insider sold shares worth $2,383,511, according to an SEC filing. The company's stock has seen a 5-day change of -1.79% and a year-to-date change of -3.24%.
Medpace director Robert O. Kraft sold 3,860 shares at an average price of $617.81, totaling $2.38M. He now owns 955 shares. The sale was reported in an SEC Form 4 filing, with transaction prices ranging from $617.73 to $618.43.
Significant insider sell may signal lack of confidence, potentially pressuring the stock.
AlphAI scores every news story that mentions MEDP with an AI model for sentiment and relevance, and aggregates insider trades from Medpace Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Troendle August J. (President & CEO) sold 24,741 shares of Medpace Holdings, Inc. (MEDP) at an average of $621.00 ($620.84–$621.29, $15.36M total) across 2 trades over 2026-09-15 to 2026-09-16.
1 min readTroendle August J. (President & CEO) sold 650 shares of Medpace Holdings, Inc. (MEDP) at $620.27 ($0.40M total) on 2026-08-27.
1 min readMedpace Holdings insider sold shares worth $2,383,511, according to an SEC filing. The company's stock has seen a 5-day change of -1.79% and a year-to-date change of -3.24%.
1 min readMedpace director Robert O. Kraft sold 3,860 shares at an average price of $617.81, totaling $2.38M. He now owns 955 shares. The sale was reported in an SEC Form 4 filing, with transaction prices ranging from $617.73 to $618.43.
1 min readKraft Robert O. sold 3,858 shares of Medpace Holdings, Inc. (MEDP) at $617.81 ($2.38M total) on 2026-08-26.
1 min readTroendle August J. (President & CEO) sold 4,673 shares of Medpace Holdings, Inc. (MEDP) at an average of $620.08 ($620.03–$620.38, $2.90M total) across 2 trades over 2026-08-25 to 2026-08-26.
1 min readMedpace CEO Troendle sold $10 million in stock, retaining 2.7 million shares. MEDP stock rose 32% in the past year, with Q4 sales and EPS up 17% and 37% respectively. The company's valuation is at 25 times free cash flow, above its 10-year average. Medpace's model may benefit from AI technology.
2 min readMedpace's President & CEO August J. Troendle sold shares worth $9.97M at weighted average prices of $624.45 and $620.23 on August 21 and 24, respectively. Troendle now directly owns 545,217 shares and indirectly owns 4,733,019 shares via Medpace Investors, LLC, according to an SEC Form 4 filing.
1 min readTroendle August J. (President & CEO) sold 15,978 shares of Medpace Holdings, Inc. (MEDP) at an average of $623.93 ($620.23–$624.45, $9.97M total) across 2 trades over 2026-08-21 to 2026-08-24.
1 min readMedpace Holdings (MEDP) CFO Kevin M. Brady sold 3,400 shares for $2.13M. Recent clinical-trial updates boosted investor sentiment. Analyst Spark rates MEDP as Outperform, citing strong financials and guidance, but notes high valuation. MEDP's YTD performance is +10.52% with a $17.33B market cap.
1 min read
